Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_assertion type Assertion NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_head.
- NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_assertion description "[In this study, we investigated the prognostic value of CTC/CSC that express carcinoembryonic antigen (CEA) cytokeratin 19 (CK19), CK20 and/or CD133 (CEA/CK/CD133) mRNA in the tumor drainage blood of CRC patients with Dukes' stage B and C. We examined tumor drainage blood from 197 patients with Dukes' stage B and C CRC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_provenance.
- NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_assertion evidence source_evidence_literature NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_provenance.
- NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_assertion SIO_000772 22267181 NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_provenance.
- NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_assertion wasDerivedFrom befree-2016 NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_provenance.
- NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_assertion wasGeneratedBy ECO_0000203 NP955181.RAKNn_tH-6y5RY-Um64hp3S_bgMVlchn4NaMZ2W9UPxcE130_provenance.